Premature Induction of an Immunosuppressive Regulatory T Cell Response during Acute Simian Immunodeficiency Virus Infection by Estes, Jacob D. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Qingsheng Li Publications Papers in the Biological Sciences
2006
Premature Induction of an Immunosuppressive
Regulatory T Cell Response during Acute Simian
Immunodeficiency Virus Infection
Jacob D. Estes
University of Minnesota, Minneapolis, estesj@mail.nih.gov
Qingsheng Li
University of Nebraska-Lincoln, qli4@unl.edu
Matthew R. Reynolds
University of Wisconsin, Madison, mrreynol@wisc.edu
Stephen W. Wietgrefe
University of Minnesota, wietg001@umn.edu
Lijie Duan
University of Minnesota, Minneapolis, duanx009@umn.edu
See next page for additional authorsFollow this and additional works at: http://digitalcommons.unl.edu/biosciqingshengli
Part of the Animal Diseases Commons, Immune System Diseases Commons, Immunity
Commons, Immunology of Infectious Disease Commons, Immunoprophylaxis and Therapy
Commons, Veterinary Infectious Diseases Commons, Veterinary Microbiology and Immunobiology
Commons, and the Virus Diseases Commons
This Article is brought to you for free and open access by the Papers in the Biological Sciences at DigitalCommons@University of Nebraska - Lincoln.
It has been accepted for inclusion in Qingsheng Li Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Estes, Jacob D.; Li, Qingsheng; Reynolds, Matthew R.; Wietgrefe, Stephen W.; Duan, Lijie; Schacker, Timothy; Picker, Louis J.;
Watkins, David I.; Lifson, Jeffrey D.; Reilly, Cavan; Carlis, John V.; and Haase, Ashley T., "Premature Induction of an
Immunosuppressive Regulatory T Cell Response during Acute Simian Immunodeficiency Virus Infection" (2006). Qingsheng Li
Publications. 16.
http://digitalcommons.unl.edu/biosciqingshengli/16
Authors
Jacob D. Estes, Qingsheng Li, Matthew R. Reynolds, Stephen W. Wietgrefe, Lijie Duan, Timothy Schacker,
Louis J. Picker, David I. Watkins, Jeffrey D. Lifson, Cavan Reilly, John V. Carlis, and Ashley T. Haase
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/biosciqingshengli/16
Generally, viral infections activate the immune system, which generates large numbers of immune cells, cyto-
kines, and other effectors that are needed to terminate the 
infection by eradicating infected cells and virus [1]. This 
initial expansion stage is followed by a contraction stage, 
during which, it is currently thought, regulatory T (Treg) 
cells play a prominent role in maintaining the delicate bal-
ance between an immune response that is sufficiently ro-
bust to clear the infection and the immunopathological 
consequences of sustained immune activation and inflam-
mation [2, 3].
Similarly, during the early stages of HIV and simian 
immunodeficiency virus (SIV) infection, viral replication 
in lymphatic tissue activates the immune system, and vi-
ral levels decrease in concert with increasing numbers 
of virus-specific cytotoxic T lymphocytes (CTLs) [4, 5]. 
However, HIV and SIV infections are typically persistent, 
with viral replication continuing because of the incom-
plete clearance of productively infected cells. Among the 
many mechanisms that contribute to the inability of CTLs 
to eliminate all of the productively infected cells, there is 
increasing evidence (particularly from the SIV-infected 
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Abstract
Here we report the results of an investigation into the possibility that one mechanism responsible for the establish-
ment of persistent human immunodeficiency virus infection is an early regulatory T (Treg) cell response that blunts vi-
rus-specific responses. Using the simian immunodeficiency virus (SIV)–infected rhesus macaque model, we show 
that, indeed, viral replication and immune activation in lymphatic tissue drive a premature immunosuppressive re-
sponse, with dramatic increases in the frequencies of CD4+CD25+FOXP3+ Treg cells, transforming growth factor–β1
+ 
cells, interleukin–10+ cells, and indoleamine 2,3-dioxygenase+CD3+ cells.When we compared SIV infection with rhe-
sus cytomegalovirus (RhCMV) infection, we found that the frequency of Treg cells paralleled the magnitude of immune 
activation during both infections but that the magnitude of immune activation and of the Treg cell response were lower 
and peaked much later during RhCMV infection. Importantly, the frequency of Treg cells inversely correlated with the 
magnitude of the SIV-specific cytotoxic T lymphocyte response. We conclude that an early Treg cell response during 
acute SIV infection may contribute to viral persistence by prematurely limiting the antiviral immune response before in-
fection is cleared.
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rhesus macaque [RM] model) indicating that the CTL re-
sponse is too little, too late [6, 7]. Because several stud-
ies have shown that the magnitude of effector T cell im-
mune responses to acute viral infections can be limited by 
Treg cells [8–10], and because Treg cells may enable some 
pathogens to establish chronic infection by blunting the 
immune response, we hypothesized that an immunosup-
pressive Treg cell response might be one mechanism that 
delays and limits the CTL response during acute lentiviral 
infection, resulting in virus-specific responses of insuffi-
cient magnitude to clear these infections. In this hypothe-
sis, the immunosuppressive Treg cell response is untimely 
or premature in that it kicks in to regulate the massive im-
mune activation and inflammation in lymphatic tissue so 
quickly that it dampens the CTL response before infected 
cells have been completely eliminated. We tested this hy-
pothesis using the SIV-infected RM model, in which we 
could examine, during the acute stage of infection, the 
relationship between viral replication and immune de-
fense and immunoregulatory responses. We show that, in 
lymphatic tissue, Treg cells and immunosuppressive me-
diators are induced so early in response to immune acti-
vation that SIV-specific CTL responses are constrained 
at just the time when they are most needed to clear the 
infection.
Materials and Methods
Animals and experimental SIV and rhesus cytomegalovirus 
(RhCMV) infections. To characterize the early Treg cell re-
sponse in lymphatic tissue, we studied tissues from 3 dif-
ferent experiments in SIV-infected RMs and from a sepa-
rate study of primary RhCMV infection. In the first study, 
lymph node (LN) tissues were obtained at necropsy from 
4 adult female Indian RMs 1–12 days after atraumatic in-
travaginal (ivag) infection, as described elsewhere [11]. In 
the second study, LN tissues were obtained at necropsy 
from 5 adult female RMs 2 h–28 days after ivag inoculation 
of TCID50 of SIVmac251 2 × 105 or SIVmac239 [12]. In the third 
study, which was longitudinal, LN biopsy samples were 
obtained from 4 adult female RMs before and 7 and 28 
days after intravenous (iv) infusion of 1 MID50 of SIVmac239.
In the fourth study, 4 CMV-negative juvenile RMs were 
subcutaneously inoculated with 1 × 106 pfu of CMV strain 
68.1 at 2 sites. LN biopsy samples were obtained 21 days 
before and 7, 14 (2 RMs), 28 (2 RMs), and 70 days after in-
fection. Tissues were snap-frozen in liquid nitrogen and 
embedded in OTC for long-term storage. All animal stud-
ies were approved by the appropriate institutional review 
board.
Immunohistochemical staining, in situ hybridization, 
quantitative image analysis, and tetramer staining. Sin-
gle immunohistochemical staining, in situ hybridization, 
and quantitative image analysis were performed as de-
scribed elsewhere [11, 13]. Antibodies used were rabbit and 
goat anti–transforming growth factor (TGF)–β1, goat anti-
FOXP3, mouse and rabbit anti–interleukin (IL)–10 (all from 
Santa Cruz Biotech), rabbit anti-FOXP3 (gift from A. Y. 
Rudensky, M. A. Gavin, and P. deRoos, Howard Hughes 
Medical Institute, University of Washington), rabbit anti-
CD3 (DakoCytomation), mouse anti– indoleamine 2,3-di-
oxygenase (IDO; Chemicon International), mouse anti-CD4 
(Novocastra Laboratories), and mouse anti-CD25 (Neo-
Markers). Anti-FOXP3 (Santa Cruz Biotech) specificity was 
determined by incubating the antibody with the FOXP3 
peptide used as the immunogen at a peptide:antibody ratio 
of 20:1 before incubation with tissue sections. Although the 
peptide-blocking treatment did not completely abrogate 
FOXP3 staining in all tissue samples, it did dramatically re-
duce the detection of FOXP3 by use of antibody (data not 
shown). Dual-label immunofluorescence confocal micros-
copy was performed as described elsewhere [13]. Tetramer 
analysis on CTLs from lymphatic tissue was performed as 
described elsewhere [14].
Statistical methods. For quantitative image-analysis 
data, the mean for each RM was derived from at least 18 
randomly acquired high-power images. The graphs show 
either individual means (for groups with n = 1) or group 
means (derived by averaging all individual RM means ± 
SEs). To assess increases in the frequency of TGF-β1+ and 
FOXP3+ cells during infection, we fit linear models for 
each protein, pooling all of the data from the RMs into 1 
model. Linearity was assessed graphically for those RMs 
with multiple measurements and was also more formally 
assessed by incorporating a quadratic termin the mod-
els; both of these strategies suggested that the linearity of 
change over time was reasonable. In a linear model that 
allowed for correlation within measurements from the 
same RM, model parameters were estimated using max-
imum likelihood (using S-plus [version 3.1, release 1], 
a statistical program from Math-Soft). To test whether 
the magnitude of the responses was increasing, we con-
ducted a hypothesis test on the slope parameter in the lin-
ear model. This test indicated that the changes observed 
for both TGF-β1+ cells and FOXP3+ cells were statisti-
cally significant (P < .0001, for both). To test for an associ-
ation between the frequency of Treg cells and the percent-
age of SL8 tetramer+CD8+ T cells, a random-effects model 
was used (using restricted maximum likelihood, as imple-
mented in the varcomp function in S-plus). This model al-
lows for testing an association when multiple measure-
ments are taken from individual subjects and one wants 
to combine these measurements. This model was also 
used to investigate the effect of LN location on the asso-
ciation; however, because no such effect was found, the 
data were aggregated.
Results
In recent experiments investigating the CTL response to 
SIV after ivag infection, we found that the response to im-
munodominant epitopes in SIV was too late in the sense 
that it was not detectable until several days after the peak 
of virus replication in lymphatic tissue [7]. Moreover, the 
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Figure 1. Dramatic increase in transforming growth factor (TGF)–β1 expression in the paracortical T cell zones of lymph nodes 
during acute simian immunodeficiency virus (SIV) infection of rhesus macaques (RMs). A, Images showing a significant increase 
in the frequency of TGF-β1+ cells (upper panels) in the paracortical T cell zones of secondary lymphatic tissue shortly after both in-
travenous (iv) and intravaginal (ivag) SIV infection (TGF-β1+ cells are indicated by brown staining; original magnification, ×400). 
Productively infected cells (lower panels) were detected by in situ hybridization within 7 days of iv infection, and the level peaked 
at 28 days after iv infection, whereas the level of productively infected cells peaked at 12 days and remained high until 21 days af-
ter ivag infection (original magnification, ×100). B, Enumeration of the frequency of TGF-β1+ cells. TGF-β1+ cells were enumer-
ated in at least 18 randomly acquired high-power images for each RM, and the graphs show either individual means (for groups 
with n = 1) or group means (derived by averaging all individual RM means ±SEs); the no. of RMs at each time point is shown in 
parentheses. To determine whether the increase in TGF-β1 expression was statistically significant over time, the data were fit into 
a model that incorporated data from all RMs and time points, as outlined in Materials and Methods. This model indicated that the 
change observed for TGF-β1 expression was statistically significant (P < .0001).
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response was too little in the sense that the number of SIV-
specific CTLs decreased from peak levels even while pro-
ductively infected cells remained in lymphatic tissue. 
To investigate the possibility that one reason for the fail-
ure to clear infection was an early immunosuppressive re-
sponse that prematurely limited the immune response 
before the infection had been cleared, we examined lym-
phatic tissue obtained during acute SIV infection, to eval-
uate the relationship that might exist between the timing 
and magnitude of immunosuppressive responses and viral 
replication.
Induction of TGF-β1+ cells during acute SIV infection. 
We began by assaying TGF-β1, a potent immunosuppres-
sive soluble mediator and major effector molecule used by 
CD4+CD25+ Treg cells. Analyzing the period from the on-
set of viral replication in lymphatic tissue (~7 days after 
infection), through the peak (10–14 days) and subsequent 
decrease of replication, and to the time of persistent infec-
tion (28 days), during which sustained levels of replication 
are characteristic [12], we quantified TGF-β1 expression in 
pooled LN biopsy samples from separate studies of acute 
infection after inoculation of SIV by iv and ivag routes.
In LN samples obtained sequentially from the same RMs 
that had been iv infected, there were few TGF-β1+ cells be-
fore infection, but, by 7 days after infection, the frequen-
cies of TGF-β1+ cells in the paracortical T cell zones had in-
creased >4-fold, and, by 28 days after infection, they had 
increased >11-fold (figure 1A and 1B). There was a simi-
lar rapid increase in LN samples obtained at necropsy from 
RMs 12, 14, and 21 days after ivag infection—the frequen-
cies of TGF-β1+ cells were >10- fold higher in infected RMs 
than in uninfected control RMs (figure 1A and 1B).
The rapidity of the TGF-β1 response was consistent 
with the hypothesis that the early peak of viral replication 
Figure 2. Dramatic increase in FOXP3+ regulatory T (Treg) cells in the paracortical T cell zones of lymph nodes during acute sim-
ian immunodeficiency virus (SIV) infection of rhesus macaques (RMs). A, Expression of FOXP3 by CD4+CD25+ Treg cells, pheno-
typically identifying them as natural Treg cells. The majority of FOXP3
+ cells were transforming growth factor–β1 and interleukin–10 
positive (original magnification, ×640). B, Rapid increase in the frequency of FOXP3+ Treg cells (brown staining) in the paracortical 
T cell zones of secondary lymphatic tissue after both intravenous and intravaginal SIV infection (original magnification, ×400). C, 
Frequency of FOXP3+ Treg cells. The frequency of FOXP3
+ Treg cells was determined and plotted as described in figure 1. To de-
termine whether the increase in FOXP3 expression was statistically significant over time, the data were fit into a model that incor-
porated data from all RMs and time points, as outlined in Materials and Methods. This model indicated that the change observed 
for FOXP3 expression was statistically significant (P < .0001).
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was driving this immunoregulatory response. Indeed, we 
found that the peak of the TGF-β1 response occurred soon 
after the peak of virus replication, from days 10 to 14. More 
importantly, the frequency of TGF-β1+ cells remained high 
when there were still significant numbers of productively 
infected cells in lymphatic tissue (figure 1A, lower panels), 
a finding that is consistent with the hypothesis that this im-
munosuppressive response is premature with respect to 
the host defense’s attempt to eradicate the infection.
Induction of CD4+CD25+FOXP3+ Treg cells during acute 
SIV infection. We next established that the TGF-β1 re-
sponse is just one manifestation of an early general im-
munosuppressive response composed of Treg cells and po-
tent immunosuppressive mediators. We quantified the Treg 
cell response by staining tissue sections for the transcrip-
tion factor that controls the generation of natural Treg cells, 
FOXP3 [15, 16], and for CD4 and CD25. The majority of the 
FOXP3+ cells (mean ± SD, 93.4% ± 4.2%) that accumulated 
rapidly in the paracortical T cell zones of secondary lym-
phatic tissue shortly after SIV infection were CD4+CD25+ 
Treg cells (figure 2A). In addition, we found that most of the 
TGF-β1+ cells (mean ± SD, 76.2% ± 6.7%) also coexpressed 
FOXP3 and were CD4+CD25+ Treg cells (figure 2A and table 
1), with the rest presumably being Th3 cells. Importantly, 
the increased frequency of FOXP3+ Treg cells in secondary 
lymphatic tissue (figure 2B and 2C) was approximately 
equal to the increased frequency of TGF-β1+ cells. Because 
human Treg cells are highly susceptible to HIV infection in 
vitro [17], we reasoned that the dramatic increase in the fre-
quency of Treg cells reported here could provide a highly 
susceptible population of target cells for further SIV propa-
gation, and we investigated the possibility that the increase 
in the frequency of Treg cells was limited by productive in-
fection. Surprisingly, at the peak of viral replication (10–14 
days after infection), we found that, on average, only 13% 
of FOXP3+ Treg cells in secondary lymphatic tissue were in-
fected (SIV RNA+; data not shown), indicating that, in vivo, 
productive infection of Treg cells does not greatly contrib-
ute to limiting the expansion of this population.
Induction of IL-10+ and IDO+CD3+ Treg cells dur-
ing acute SIV infection. Because IL-10 has been shown to 
be a potent immunosuppressive mediator in a variety of 
settings and can be expressed by both natural Treg cells and 
type 1 Treg cells, we investigated changes in the frequency 
of IL-10+ cells (figure 3A). We found that the frequency of 
IL-10+ cells increased as early as 7 days after infection with 
a dramatic increase by 28 days, which was similar in mag-
nitude and timing to the increased frequency of TGF-β1+ 
cells and FOXP3+ Treg cells. Moreover, we also found in-
creased frequencies of cells expressing IDO (figure 3B), an 
interferon (IFN)–γ inducible enzyme that generates such 
highly immunosuppressive byproducts as n-formylkyn-
urenine by oxidative degradation of tryptophan.We sus-
pected that tolerogenic dendritic cells (DCs) might be the 
source of the IDO, on the basis of the study by Munn et 
al. demonstrating the existence of a subset of monocyte-de-
rived DCs that use this enzyme to suppress T cell prolifer-
ation in vitro [18]. However, we found that, during acute 
SIV infection, most of the IDO+ cells were CD3+ T cells (fig-
ure 3B) and that most were, in fact, FOXP3+ Treg cells (mean 
± SD, 83.1% ± 10.6%). Moreover, a detailed analysis of the 
phenotype of Treg cells at peak induction revealed a highly 
heterogeneous Treg cell population that included natural 
Treg cells (FOXP3+), Th3 cells (FOXP3–TGF-β+), and type 1 
Treg cells (FOXP3–IL10+) (table 1). On the basis of the strong 
correlation between the frequency of CD4+FOXP3+ cells 
and the frequencies of TGF-β1+, IL-10+, and IDO+CD3+ 
cells, we conclude that a heterogeneous population of Treg 
cells expressing several powerful immunosuppressive me-
diators is induced during acute SIV infection.
Kinetics of induction of Treg cells parallel kinetics of 
immune activation but differ during SIV and RhCMV in-
fection. We hypothesized that the immune activation that 
accompanied viral replication in SIV-infected LNs was 
driving the early induction of the immunosuppressive re-
sponse, and we tested this hypothesis in 2 ways: (1) by 
characterizing the relationship between the kinetics of the 
induction of Treg cells and the kinetics of immune activa-
tion during SIV infection and (2) by comparing this rela-
tionship with that for infection with another virus, Rh-
CMV, during which immune activation occurs later and in 
response to antigenic stimulation only, rather than to the 
combined effect of antigenic stimulation and viral infec-
tion in lymphatic tissue, as is the case for SIV. Consistent 
Table 1. In vivo phenotype of regulatory T (Treg) cells expressed in lymph nodes from simian immunodeficiency virus–
infected rhesus macaques 14 days after infection.
Cell type FOXP3+ TGF-β1+ IL-10+ IDO+
Natural Treg cells (FOXP3
+) … 67.5 ± 13.8 (36.1–93.9) 58.3 ± 7.5 (46.8–70.6) 83.0 ± 11.9 (62.2–100)
Th3 cells (TGF-β1+) 76.2 ± 16.7 (53.2–97.2) … ND ND
Type 1 Treg cells (IL-10
+) 67.9 ± 9.2 (51.5–89.4) ND … ND
Data are the mean ± SD (range) percentage of cells in the left column expressing the antigen listed at top. Eighteen randomly 
acquired high-power confocal images were obtained and processed in Photoshop, and quantitative image analysis was per-
formed to determine the colocalization of the 2 different antigens of interest. IDO, indoleamine 2,3-dioxygenase; IL, interleukin; 
ND, not determined; TGF, transforming growth factor.
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with this hypothesis, we found that the kinetics of the in-
duction of FOXP3+ Treg cells paralleled the kinetics of im-
mune activation (Ki67+ cells) in the paracortical T cell 
zones of secondary lymphatic tissue from 4 RMs after iv 
SIV infection (figure 4A). In addition, we found that, al-
though there was a positive correlation between the fre-
quency of Treg cells and that of SIV RNA+ cells (r = 0.5969), 
there was a much stronger relationship between the fre-
quency of Treg cells and the magnitude of the immune ac-
tivation (r = 0.8967) (figure 4B). To examine how the fre-
quency of SIV RNA+ cells and the magnitude of immune 
activation simultaneously impact the frequency of Treg 
cells, we fit a multiple regression model to the data on all 
RMs using all variables. The results of this model indicated 
that, although the frequency of SIV RNA+ cells was related 
to the frequency of Treg cells, when considering the effect of 
SIV infection on the frequency of Treg cells given the effect 
of immune activation, there was not a statistically signifi-
cant relationship. However, there was a statistically signif-
icant relationship between the magnitude of immune acti-
vation and the frequency of Treg cells given the effect of SIV 
infection (P = 0006). Therefore, this model indicates that the 
Figure 3. Rapid induction of immunosuppressive interleukin (IL)–10 and indoleamine 2,3-dioxygenase (IDO) in the paracortical 
T cell zones of lymph nodes during acute simian immunodeficiency virus (SIV) infection of rhesus macaques. The frequencies of 
both IL-10+ cells (A) and IDO+ cells (B; left panels) increased shortly after both intravenous and intravaginal SIV infection. Most 
IDO+ cells were CD3+ T cells (B; right panel), not dendritic cells (as determined on the basis of phenotypic analysis of dual-stained 
tissue at peak expression of IDO) (original magnification, ×400).
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weaker relationship we observed between the frequency of 
SIV RNA+ cells and the frequency of Treg cells reflects the 
stronger association between the frequency of Treg cells and 
the magnitude of immune activation and the relationship 
between the magnitude of immune activation and the level 
of SIV infection. We think that these data support the hy-
pothesis that viral replication indirectly drives the induc-
tion of Treg cells by inducing a massive state of immune 
activation.
In contrast, in the RhCMV-infected RMs, immune acti-
vation within the paracortical T cell zones was not evident 
until 70 days after infection, and the peak Treg cell response 
was correspondingly delayed and of lower magnitude (fig-
ure 4C). Immune activation in the RhCMV-infected RMs 
likely occurred in response to persistent systemic infection 
at other anatomic sites, because we did not detect any IE-1+ 
(immediate early–1 gene product) or pp65+ (matrix phos-
phoprotein–65 late gene product) productively RhCMV-in-
fected cells in the LN samples by immunohistochemistry 
or sensitive polymerase chain reaction techniques (data 
not shown). Thus, for both infections, immune activation 
is correlated with a counterbalancing Treg cell response, 
but the timing is different. Most importantly, the replica-
tion- driven immune activation that occurs early during 
SIV infection induces a rapid Treg cell response that has the 
potential to negatively impact the host cellular immune re-
sponse to infection while replication continues.
Impact of Treg cells on the CTL response during acute 
SIV infection. To test the hypothesis that the early induc-
tion of the Treg cell response to counter immune activa-
tion and inflammation in SIV-infected lymphatic tissues 
might, in fact, detrimentally affect SIV-specific immune re-
sponses, we compared the frequency of FOXP3+ Treg cells 
to the percentage of SIV-specific CTLs that recognized SL8 
(aa 28–35), an immunodominant epitope in Tat that has 
been shown to exert strong selective pressure on SIV (fig-
ure 5) [19]. We quantified the SL8 tetramer+CD8+ T cell re-
sponses in 5 Mamu-A*01 major histocompatibility complex 
Figure 4. Regulatory T (Treg) cell generation is driven by immune activation in the paracortical T cell zones of lymph nodes dur-
ing acute simian immunodeficiency virus (SIV) infection of rhesus macaques (RMs). Changes in the frequency of Ki67+ cells mir-
rored the level of Treg cell expression from 7 to 28 days after intravenous infection (A), and a strong relationship existed between 
the frequency of Treg cells and the magnitude of immune activation (B); in contrast, primary rhesus cytomegalovirus (RhCMV)–in-
fected RMs showed a delayed induction of FOXP3+ Treg cells associated with T cell zone immune activation (Ki67
+ cells) (C; origi-
nal magnification, ×400 for FOXP3 and ×100 for Ki67; “TZ” indicates T cell zones, and “GC” indicates germinal centers).
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class I allele–positive RMs, and we detected significant 
percentages (1.25%–4.61%) of SL8 tetramer+ CD8+ T cells 
in 2 of them (RM 1919 and RM 27099). In contrast, the SL8 
responses were low (0.01%–0.8%) or undetectable in the 
other 3 RMs. There was a significant inverse correlation 
between the frequency of Treg cells and the percentage of 
SL8 tetramer+CD8+ T cells at 21 and 28 days after infec-
tion (r = 0.812; P < .01) (figure 5), which is consistent with 
the idea that Treg cells inhibit the CTL response to the im-
munodominant epitope SL8, which has been shown to 
play such an important role in the initial partial control of 
infection.
Discussion
Shortly after infectious challenges, specific host adaptive 
immune responses are initiated to combat these patholog-
ical threats. Most pathogens are effectively contained and 
then eliminated from the host by these responses; in some 
cases, however, the infectious agent is only partially con-
trolled and is not eradicated, resulting in long-term per-
sistent infections, immune hyperactivation, and immune-
mediated tissue damage [20]. Understanding why the 
immune system fails to control these infectious pathogens 
is of great interest, particularly for persistent viral infec-
tions that result in high morbidity and mortality, such as 
infection with hepatitis C virus and HIV. Here, we provide 
evidence that one mechanism for lentiviral persistence may 
be a massive immunosuppressive regulatory response in-
duced by the host shortly after viral exposure in secondary 
lymphatic tissues in response to corresponding viral repli-
cation and immune activation.
There is a growing body of evidence that Treg cells sup-
press effector immune responses by a variety of mech-
anisms [8, 9, 15, 20–31]. In addition, it has recently been 
shown that Treg cells not only regulate herpes simplex vi-
rus–specific CTL responses but may also suppress HIV-
specific T cell responses during chronic infection, thus di-
minishing the magnitude of the immune response to these 
viral pathogens [8, 32–38]. Recently, Haeryfar et al. [39] 
showed that depleting Treg cells significantly enhanced the 
magnitude of the CTL response to influenza A virus–, vac-
cinia virus–, and simian virus 40–transformed cells in vivo. 
These and our present data support a role for Treg cells in 
controlling the magnitude of CTL responses in vivo, likely 
through inhibiting T cell proliferation and clonal expan-
sion. To add to the growing evidence for control of patho-
genic immune responses by Treg cells, we show here for the 
first time that, during acute SIV infection, the magnitude 
of the SIVspecific CTL response to the Tat immunodomi-
nant epitope SL8 is inversely related to the magnitude of 
the immunosuppressive Treg cell response. In addition, pre-
liminary results indicate that RMs with high frequencies of 
Treg cells in secondary lymphatic tissues have significantly 
lower frequencies of both IFN-γ+ cells and IL-12+ cells, 
compared with those in RMs with low frequencies of Treg 
cells (authors’ unpublished data). Furthermore, the pres-
ent study indicates that the anatomical distribution of Treg 
cells in vivo is primarily contained within the paracortical 
T cell zones of secondary lymphatic tissue, the immune in-
ductive site for the stimulation and activation of effector T 
cell responses.
Our data suggest that the early, sustained immunosup-
pressive response is composed, in large part, of TGF-β1+ 
Treg cells. In the SIV-infected RM model, there are currently 
no experimental approaches to show in tissue that the ini-
tial Treg cell response is antigen specific, as has been shown 
both in vitro and in vivo in other systems [15, 16, 40, 41], 
but we reason that the early Treg cell response generated 
shortly after SIV exposure is a consequence of immune ac-
tivation of resident SIV-specific Treg cells in secondary lym-
phatic tissue. However, it is likely that, by the peak of this 
Treg cell response, the production of immunosuppressive 
effector cytokines (such as TGF-β1) by antigen-specific Treg 
cells may drive the induction of nonspecific inducible “by-
stander” Treg cells, further amplifying the immunosuppres-
sive response.
What roles TGF-β1 and IL-10 play in the in vivo func-
tion of CD4+CD25+ natural Treg cells are still quite contro-
versial. Although most in vitro studies have shown that 
CD4+CD25+ Treg cells do not mediate immunosuppres-
sion via soluble factors, several in vivo studies have dem-
onstrated the importance of TGFb1 and IL-10 in immuno-
suppression mediated by CD4+CD25+ Treg cells [42–47]. 
The present study, which demonstrated the expression of 
Figure 5. Significant inverse correlation between the fre-
quency of FOXP3+ regulatory T (Treg) cells and the magnitude 
of the cytotoxic T lymphocyte (CTL) response to the Tat im-
munodominant epitope SL8. Tetramer analysis was performed 
on CTLs that had been isolated from a portion of the obturator 
(circles), inguinal (squares), and mesenteric (triangles) lymph 
nodes (LNs) from 5 Mamu-A*01 major histocompatibility com-
plex class I allele–positive rhesus macaques (21–28 days af-
ter infection). The frequency of Treg cells was determined on 
the basis of tissue sections from the same LNs, as described 
in Materials and Methods. The relationship was highly signifi-
cant (P < .01), as determined on the basis of a test of the re-
gression slope in a random effects model, which is described 
in detail in Materials and Methods.
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TGF-β1 and IL-10 by CD4+CD25+FOXP3+ Treg cells, pro-
vides further evidence indicating that natural Treg cells 
likely use either or both TGF-β1 and IL-10 as mechanisms 
for immunosuppression in vivo and shows for the first 
time that most natural Treg cells also express the highly im-
munosuppressive enzyme IDO, which represents another 
mechanism for immunosuppression mediated by Treg cells.
The induction of Treg cells during acute SIV infection 
likely parallels the induction of immune activation in the 
paracortical T cell zones of secondary lymphatic tissue as 
a response by the host to control immune-mediated path-
ological damage due to immune hyperactivation. How-
ever, this Treg cell response dose not appear to be capable 
of limiting the massive hyperactivation in the lymphatic 
compartments during acute SIV infection in RMs. In con-
trast, a recent study by Kornfeld et al. indicates that, during 
the course of natural infection in African green monkeys 
(AGMs) infected with SIVagm, a very rapid immunosup-
pressive response is induced and peaks during the first 
week of infection, followed by a decease to baseline levels 
[48]. The much more rapid immunosuppressive response 
in AGMs abrogates immune hyperactivation, resulting in 
a far more benign disease outcome in comparison with that 
in RMs. Thus, the timing of the Treg cell response in rela-
tion to immune activation and the adaptive immune re-
sponse is the critical determinant of outcome. The Treg cell 
response in SIV-infected RMs is too late to counterbalance 
and prevent the immunopathological consequences of sus-
tained immune activation and is too early and untimely 
with respect to immune control, as it down-regulates im-
portant effector T cell responses before immune control is 
achieved. In AGMs, the Treg cell response is also too early 
to prevent a persistent infection, with viral replication at 
levels comparable with those in SIV-infected RMs, but is 
sufficiently early to prevent the immunopathological ef-
fects of sustained immune activation.
In summary, we have shown that SIV infection elicits an 
early Treg cell response in secondary lymphatic tissue, one 
likely driven by the immune activation associated with in-
fection. Although this immunosuppressive response may 
limit the immunopathological effects of sustained im-
mune activation and inflammation, the Treg cell response 
may also limit SIV-specific immune responses at just the 
time when they are critically needed to clear an infection. 
We think that a successful vaccine will need to establish a 
better balance between these beneficial and adverse effects 
of Treg cell responses, and we speculate that there may be 
a role for anti-inflammatory treatment during acute infec-
tion, to moderate the Treg cell response.
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